Xencor Strengthens Antibody Therapeutics Patent Portfolio with Exclusive License from the University of Cambridge.MONROVIA, Calif. -- Xencor, Inc. signed an agreement to exclusively license technology developed at the University of Cambridge that enables the creation of monoclonal antibodies This is a list of monoclonal antibodies, antibodies which are clones of a single parent cell. When used as medications, the generic names end in -mab (see "Nomenclature of monoclonal antibodies"). with greatly enhanced potency potency /po·ten·cy/ (po´ten-se) 1. the ability of the male to perform coitus. 2. the relationship between the therapeutic effect of a drug and the dose necessary to achieve that effect. 3. . The technology includes specific Fc (antibody constant region) variants that complement Xencor's proprietary suite of XmAb(TM) engineered Fc domains, which are designed to enhance the therapeutic properties of monoclonal antibodies. Xencor's XmAb(TM) antibody Fc domains can be inserted into antibody candidates against any target antigen and may improve multiple important effector effector /ef·fec·tor/ (e-fek´ter) 1. an agent that mediates a specific effect. 2. an organ that produces an effect in response to nerve stimulation. functions, including enhanced antibody-mediated tumor tumor: see neoplasm. cell killing, sustained half-life and increased structural stability. "Our XmAb(TM) technology has enabled us to develop a large and growing portfolio of Fc variants, and we are aggressively establishing additional IP in this area by licensing complementary technologies," said Bassil Dahiyat, Ph.D., President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Xencor. "Our strategy is to create potent antibody therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. by exploiting our suite of Fc variants that maximally max·i·mal adj. 1. Of, relating to, or consisting of a maximum. 2. Being the greatest or highest possible. n. Mathematics An element in an ordered set that is followed by no other. enhance Fc-mediated effector function and offer a very broad range of therapeutic properties. This license further bolsters our leading proprietary position." Dr. Anne Dobree, Interim Director of Cambridge Enterprise, said, "We are pleased to have negotiated this license with Xencor, the most innovative company in the rapidly developing field of the engineering of antibody constant regions. Drs. Kathryn Armour and Mike Clark from the Department of Pathology discovered that a specific substitution to a sequence in part of the antibody's structure can make it much more effective. Antibodies with this change are likely to show enhanced effectiveness in killing cancer cells cells once believed to be peculiar to cancers, but now know to be epithelial cells differing in no respect from those found elsewhere in the body, and distinguished only by peculiarity of location and grouping. See also: Cancer , and also improvements in other antibody based therapies." About XmAb(TM) Antibodies Xencor's XmAb engineered Fc domains are designed to enhance the therapeutic properties of monoclonal antibodies and form a leading proprietary position in Fc engineering. Xencor's Fc domains can be inserted into antibody candidates against any target antigen and may improve one or more important effector functions, including enhanced antibody-mediated tumor cell killing, sustained half-life and increased structural stability. XmAb antibodies are produced using conventional expression and manufacturing processes. Xencor has also restored effector functions in aglycosylated antibodies, thereby creating an opportunity to use alternative expression systems with the potential of significantly lower cost of goods. Xencor is creating a pipeline of XmAb antibody drug candidates with enhanced potency and pharmaceutical properties. About Xencor Xencor, Inc., engineers superior biotherapeutics using its proprietary Protein Design Automation(R) technology platform. The company is internally advancing both XPro(TM) protein therapeutic candidates and XmAb(TM) antibody drug candidates optimized for activity against biologically validated targets. Xencor's product development is led by a protein therapeutic drug candidate, XPro1595, for the treatment of arthritis and other rheumatic rheu·mat·ic adj. Relating to or characterized by rheumatism. n. One who is affected by rheumatism. rheumatic pertaining to or affected with rheumatism. disorders and antibody candidates for the treatment of cancer. With multiple partners such as industry leaders Genentech and Centocor, Xencor is applying its suite of XmAb antibody Fc domains to improve antibody drug candidates for traits such as potency and sustained half-life. Xencor also develops therapeutic protein variants in collaboration with major pharmaceutical partners. For more information, please visit www.xencor.com. About Cambridge Enterprise Cambridge Enterprise facilitates the commercial development of University of Cambridge's intellectual property. Specialist technology transfer staff manage all aspects of patents, copyright and contractual arrangements. Cambridge Enterprise licenses patents and other intellectual property to existing companies, both large and small, as well as to spinouts formed to exploit University technology. Working together with venture capital funds Venture Capital Funds An investment fund that manages money from investors seeking private equity stakes in small and medium-size enterprises with strong growth potential. Notes: and private investors, Cambridge Enterprise generates companies with strong commercial potential. During 2004-5 the University applied for 43 patents based on 127 invention disclosures, while a total of 40 new licenses and other commercial agreements were completed. Income from patent and software licenses In computing, software that is copyrighted and licensed under a software license is done under a variety of licensing schemes. For end-users there are proprietary licenses and there are free software licenses, and there are proprietary Within these schemes are further classifications. exceeded GBP GBP In currencies, this is the abbreviation for the British Pound. Notes: The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. 2.5m, and demand for academics' technical advice added a further GBP 1.5 million of revenue. Three new University spin-out companies were launched. Cambridge Enterprise is at http://www.enterprise.cam.ac.uk/. |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion